Lartesertib

CAS No. 2495096-26-7

Lartesertib( —— )

Catalog No. M35661 CAS No. 2495096-26-7

Lartesertib (ATM Inhibitor-5) is an inhibitor of serine/threonine protein kinase ATM with potential anticancer activity for the study of lung cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 345 In Stock
2MG 186 In Stock
5MG 312 In Stock
10MG 534 In Stock
25MG 1036 In Stock
50MG 1693 In Stock
100MG 2623 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Lartesertib
  • Note
    Research use only, not for human use.
  • Brief Description
    Lartesertib (ATM Inhibitor-5) is an inhibitor of serine/threonine protein kinase ATM with potential anticancer activity for the study of lung cancer.
  • Description
    Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    ATM/ATR
  • Recptor
    ATM/ATR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2495096-26-7
  • Formula Weight
    448.45
  • Molecular Formula
    C23H21FN6O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 100 mg/mL (222.99 mM)
  • SMILES
    COc1cncc(F)c1-n1c2c(cnc3cc(OC)c(cc23)-c2cn(C)nc2C)n(C)c1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Alessandra AMBRUOSI, et al. Pharmaceutical preparation. WO2022058351A1.
molnova catalog
related products
  • AZ-32

    AZ32 is an orally bioavailable and blood-brain barrier-penetrating inhibitor of ATM(IC50 of <6.2 nM and 0.31 μM for ATM enzyme and in cell).

  • BAY-1895344

    BAY-1895344 is a potent, selective, orally active ATR inhibitor with low-nanomolar potency; potently inhibits the proliferation of a broad spectrum of human tumor cell lines with mean IC50 of 78 nM; inhibits hydroxyurea-induced H2AX phosphorylation, exhibits strong in vivo anti-tumor efficacy in monotherapy in a variety of xenograft models.Blood Cancer,Phase 1 Clinical

  • Ro 90-7501

    Ro 90-7501 is an amyloid β42 (Aβ42) protofibrillar and TPR-dependent PP5 inhibitor, a novel radiosensitizer for cervical cancer cells, which inhibits ATM phosphorylation, promotes apoptosis, and induces cell-cycle arrest.